The SMA Market: Assessing The Unknowns

Treatment Progress Leads To New Challenges In Spinal Muscular Atrophy

The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.

IV1911_SMA_550915870_1200.jpg
Uncertainty Ahead In SMA • Source: Shutterstock

The landmark FDA approval of Novartis AG’s Zolgensma (onasemnogene abeparvovec-xioi) in May 2019 shook the biopharma world in several ways including its price ($2.1 million per dose) and, as important, the very small data set on which FDA primarily based its decision – an ongoing open-label single arm trial of 21 infantile-onset patients with spinal muscular atrophy (SMA) under two years old. Biogen Inc.’s Spinraza (nusinersen) had already been approved in SMA in December 2016. As disease-modifying therapies, these compounds are a rarity in the field of neuromuscular diseases of genetic origin. They are also at the core of a fascinating, ongoing real-world case study in how the natural course of a disease can change rapidly. How companies’ SMA drug development and market access strategies evolve, both in terms of new disease-modifying agents and supportive therapies that address residual symptoms, could become a blueprint for other neuromuscular diseases like Duchenne’s Muscular Dystrophy (DMD) or Huntington’s Disease.

Spinal muscular atrophy (SMA) is a genetic disease caused by an absence of or defect in the SMN1 gene, which...

More from Innovation

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.